TA | Drug | MOA | Indication | Status | ANDA Cooperation Opportunity |
TUMOR | Afatinib tablet | EGFR tyrosine kinase inhibitors | Metastatic non-small cell lung cancer | IND filing in China | OPEN |
Veliparib Capsule | PAR inhibitor | Triple-negative breast cancer and metastatic non-small cell lung cancer | Process R&D | OPEN |
Lenvatin- ibMesylate Capsule | VEGFR FGFR PDGFR Multiple target tyrosine kinase inhibitors | Thyroid cancer, renal cell carcinoma and liver cancer | Process R&D | OPEN |
CVD | Rivarox- aban tablet | Xa factor inhibitor | Reduction Of Risk Of Stroke And Systemic Embolism In Nonvalvular Atrial Fibrillation Treatment Of Deep Vein Thrombos is Treatment Of Pulmonary Embolism Reduction In The Risk Of Recurrence Of Deep Vein Thrombosis And Of Pulmonary Embolism Prophylaxis Of Deep Vein Thrombosis Following Hip Or Knee Replacement Surgery | Pre-MA in China |
OPEN for International |
Metabolic Disorders | Dapaglif- lozin tablet | SGLT2 inhibitor | type 2 diabetes | IND filed in China | OPEN or International |
Empaglif- lozin tablet | SGLT2 inhibitor | type 2 diabetes | IND filed in China | OPEN |
Immu. | Apremilast tablet | PDE4 inhibitor | Psoriatic Arthritis or Psoriasis | IND approved in China | OPEN |
Tofacitinib citrateexte- nded release | JAK1/JAK3 Tyrosine protein kinase inhibitor | Rheumatoid Arthritis | IND in China | OPEN |
CK | Ferric carboxyma- ltose injection | sugar polymer releasing iron | iron deficiency anemia | IND filing in China | OPEN |
Ferric Citrate Tablet | Phosphate binder | control of serum phosphorus levels | IND filing in China | OPEN |
CNS | Safinamide tablet | Reversible monoamine oxidase inhibitor | Advanced PD | Process R&D | OPEN |
rivastigmine transdermal patch | Acetylchol- inesterase inhibitors | Alzheimer's Disease Parkinson's Disease Dementia | Process R&D | OPEN |
Pimavans- erin tablet | 5-HT2a inverse agonist | hallucinations and delusions associated with Parkinson's disease psychosis | Process R&D | OPEN |
aripipra- zolelauroxil Sustain- edrelease injection suspension | 5-HT 2A receptor inhibitors, 5-HT 1a and dopamine D2 partial agonists | schizophrenia | Process R&D | OPEN |
Brexpipra- zole tablet | Partial activation of dopamine D2 and 5-HT receptors | major depressive disorder | Process R&D | OPEN |
Vortioxetine tablet | 5-HT subtype receptor antagonists and partial agonists | major depressive disorder | Process R&D | OPEN |
Brivaraceta tablet | High efficient selective binding of synaptic vesicle protein 2A(SV2A) | adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy. | Process R&D | OPEN |
Pregab- alin capsule | Gamma aminobutyric acid (GABA) receptor agonist | Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury | ? | OPEN |
Anesthesia | Remimazo- lam injection | GABAA receptor agonist | Ultra short acting sedative anesthesia | Process R&D | OPEN |
Sugamma- dex sodium injection | GABAA receptor agonist | reversal of neuromuscular blockade induced by rocuronium bromide and vecuron- iumbromide inadults undergoing surgery. | Process R&D | OPEN |
Urinary | Oxybutynin gel | M1, M2 and M3 muscarinic receptor antagonist | overactive bladder with symptoms | IND approved in China | OPEN |
Anti | Amoxicillin Pulse release tablets | Semisyn- thetic antibiotics | Streptococcus pyogenes and / or pharyngitis tonsillitis | IND approved in China | OPEN |
Delafloxacin tablet and injection | Broad- spectrum fluoroq- uinolone antibiotics | Acute bacterial skin and skin structure infections | Process R&D | OPEN |
![ANDA R&D ANDA R&D]()
|